Proposed merger between Oncology Venture and Medical Prognosis Institute
Hørsholm, Denmark – Oncology Venture Sweden AB (publ) (“Oncology Venture” or “OV”) (AktieTorget: OV) and Medical Prognosis Institute A/S (“MPI”) (Nasdaq First North Stockholm: MPI) today jointly announce that their respective Boards of Directors have agreed on a joint merger plan (the “Merger Plan”) to accomplish a merger of the companies (the “Merger”). Combining these two highly complementary businesses will result in a leading integrated oncology biotechnology company with a promising anticancer drug pipeline (OV) resting on a proprietary patient screening technology to predict drug